CompareMona.healthvsSully.ai

Mona.health is an AI retinal screening company for diabetic eye and retinal screening programs, flagging signs of eye disease to support screening and care routing.

1. Buyer fit: Diabetic eye and retinal screening programs are the core audience, with ophthalmology depth and primary care deployment central to its positioning.
2. Workflow boundary: Mona.health supports retinal screening and care routing rather than replacing ophthalmologists; every positive screen still requires specialist follow-up.
3. Implementation checks: Buyers should confirm regulatory clearance, camera and imaging hardware compatibility, downstream referral integration, and program reporting before launch.
4. Commercial approach: Pricing is sales-led and scoped per buyer rather than posted publicly; a focused pilot within one workflow is the cleanest way to test fit.

Overall, Mona.health fits teams seeking retinal screening detection that can support specialist follow-up and implementation.

Sully.ai is an AI medical scribe and clinical assistant for clinics and physician practices, supporting ambient capture, structured note drafting, and documentation workflows.

1. Clinical role: It supports documentation rather than autonomous clinical decision-making, so clinician review of every drafted note remains essential before sign-off.
2. Best-fit environment: Clinics and physician practices may benefit most when specialty requirements and EHR workflows align with the product’s documentation approach.
3. Implementation checks: Buyers should assess specialty fit, EHR integration depth, documentation accuracy, clinician training, and rollout requirements before deployment.
4. Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, making implementation scope an important purchasing consideration.

Sully.ai is best evaluated through a focused workflow pilot that tests documentation fit, clinician review, and readiness before scaling across teams.